Clinical Trial Update: A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice

View source ↗

Summary

A cross-sectional real-world study assessing the effectiveness and safety of Kesimpta (ofatumumab) in patients with relapsing multiple sclerosis in Spanish clin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Kesimpta (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Forms of Multiple Sclerosis | Status: COMPLETED